Results 251 to 260 of about 11,167,014 (325)

Sustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndrome

open access: yes
HemaSphere, Volume 10, Issue 11, November 2026.
Bhavisha A. Patel   +34 more
wiley   +1 more source

Prevalence of Hepatitis C Infection and Treatment Initiation Following Dried Blood Spot Testing in New South Wales, Australia

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background and Aims To achieve hepatitis C (HCV) elimination by 2030, testing and treatment must reach people most at risk. Dried blood spot (DBS) testing offers an alternative to venepuncture, suitable for community and prison settings. This study evaluated HCV infection prevalence and treatment initiation among people receiving DBS testing ...
Annabelle Stevens   +12 more
wiley   +1 more source

Fucosylation limits ADCC in clinically used anti‐RhD monoclonal antibodies

open access: yesTransfusion, Volume 66, Issue 11, Page 2360-2372, November 2026.
Abstract Background Haemolytic disease of the fetus and newborn (HDFN) is caused by maternal alloantibodies, often targeting the D antigen on fetal red blood cells. Maternal immunization is preventable with timely administration of anti‐D polyclonal antibodies (pAbs).
Gabriela Koike   +33 more
wiley   +1 more source

Investigating the molecular basis of the serological Rh D‐negative phenotype in Indonesia: nature, frequency, and impact for diagnostics

open access: yesTransfusion, Volume 66, Issue 11, Page 2244-2252, November 2026.
Abstract Background Although widely studied and reported for more than 30 years, the molecular basis of Rh D‐negativity has remained unexplored in several regions of the world, including in Indonesia, Southeast Asia. Study Design and Methods A subset of 436 Indonesian blood donors originally typed D‐negative (D–) by routine serological testing was ...
Tonny Wongso   +11 more
wiley   +1 more source

AABB survey on directed blood donation practices

open access: yesTransfusion, Volume 66, Issue 11, Page 2233-2243, November 2026.
Abstract Background Standardized guidance regarding the processes for collecting directed blood donations (DBD) is lacking, leading to variable practices. This study assessed laboratory, clinical, and charging practices for DBD collection in the United States and Canada. Study Design and Methods An electronic survey was distributed to United States and
Nabiha H. Saifee   +6 more
wiley   +1 more source

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation

open access: yesTransfusion, Volume 66, Issue 11, Page 2302-2312, November 2026.
Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these ...
Anna Söderström   +8 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

open access: yesTransfusion, Volume 66, Issue 11, Page 2421-2431, November 2026.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman   +4 more
wiley   +1 more source

Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding

open access: yesTransfusion, Volume 66, Issue 11, Page 2323-2334, November 2026.
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim   +5 more
wiley   +1 more source

Mapping obstetric biobanks: A scoping review highlighting gaps in the study of alloimmunized pregnancies

open access: yesTransfusion, Volume 66, Issue 11, Page 2373-2384, November 2026.
Abstract Background Maternal red cell alloimmunization can cause hemolytic disease of the fetus and newborn (HDFN), yet prediction of disease severity remains limited. Biobanks that link pregnancy biospecimens with clinical and laboratory data could accelerate translational research; however, the landscape of relevant obstetric biobanks has not been ...
Orlin Chowdhury   +10 more
wiley   +1 more source

Implementation of soluble CD38 in blood crossmatching for patients on anti‐CD38 therapy: A single‐center experience

open access: yesTransfusion, Volume 66, Issue 11, Page 2097-2100, November 2026.
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy